Amneal Pharmaceuticals, Inc. (AMRX) Análisis de acciones

Descripción de la empresa

Amneal Pharmaceuticals, Inc. operates as a global biopharmaceutical entity dedicated to the development, manufacturing, marketing, and distribution of generic drugs, injectables, biosimilars, and specialty branded pharmaceutical products across the United States, India, Ireland, and international markets. The company functions within the Healthcare sector, specifically under the Drug Manufacturers - Specialty & Generic industry classification, which defines its role in providing essential medication alternatives and specialized therapies. Amneal Pharmaceuticals, Inc. currently holds a market capitalization of $3.78B and generates annual revenue of $3.02B while employing a workforce of 8,700 individuals. These valuation and revenue figures indicate that the company maintains a significant presence in the pharmaceutical supply chain, reflecting a substantial scale of operations that supports its diverse product portfolio across multiple geographic regions.

Salud financiera

The company reported a revenue of $3.02B for the trailing twelve months, with a net income of $72.06M and an EBITDA of $644.27M. The substantial disparity between the $3.02B in revenue and the $72.06M in net income highlights a cost structure where operating expenses, including cost of goods sold, selling, general, and administrative costs, consume a significant portion of top-line sales before reaching the bottom line. The firm generated $197.07M in free cash flow, which provides a measure of financial flexibility to fund capital expenditures, manage debt obligations, or pursue strategic acquisitions without immediate reliance on external financing. Margin analysis reveals a gross margin of 37.4%, indicating the profitability of core production activities; an operating margin of 14.1%, which reflects efficiency in managing overhead and operational costs; and a profit margin of 2.4%, demonstrating the final percentage of revenue retained as profit after all expenses. The balance sheet shows a cash position of $286.47M against total debt of $2.69B, resulting in a debt-to-equity ratio of 45095.52, which suggests a highly leveraged capital structure where liabilities significantly exceed equity. Despite the high leverage, the current ratio stands at 2.17, indicating that the company possesses more than double the current assets necessary to cover its short-term liabilities, pointing to adequate short-term liquidity. Return on Equity is listed as N/A, while Return on Assets is 7.3%, a metric that isolates how effectively management utilizes the company's total asset base to generate earnings relative to the capital invested.

Evaluación de valoración

The stock carries a P/E Ratio (TTM) of 53.86 compared to a Forward P/E of 10.07, a stark divergence that implies the market currently prices in significantly higher future earnings growth than historical performance suggests. The Price to Book ratio is -52.67, a negative figure that indicates the market capitalization is priced below the company's book value, often signaling that intangible assets or goodwill are not fully reflected on the balance sheet or that the equity value is heavily diluted by debt. Alternative valuation metrics include a Price to Sales ratio of 1.25 and an EV/EBITDA of 9.63, which provide context on the company's valuation relative to its sales volume and cash generation capabilities independent of its specific capital structure. Price metrics show a 52-Week High of $15.42 and a 52-Week Low of $6.68, establishing a trading range where the current valuation sits within the historical volatility observed over the past year. The Beta is 1.30, meaning the stock exhibits 30% higher volatility than the broader market, indicating that price fluctuations will be more pronounced during periods of market stress or rally.

Growth & Income

Revenue growth for the trailing twelve months stands at 11.5%, while earnings growth is listed as N/A due to the specific reporting metrics provided. The absence of reported earnings growth data prevents a direct comparison between revenue expansion and profit acceleration, though the revenue increase suggests successful top-line execution in a competitive generic drug market. As a non-dividend payer, the company reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, indicating that the firm chooses to retain all earnings rather than distribute them to shareholders. This retention strategy aligns with the company's need to reinvest capital into research, development, and manufacturing capacity to sustain its growth trajectory in the specialty and generic pharmaceutical sectors. The overall growth and income profile is characterized by strong revenue expansion and a complete reinvestment of profits, with no current distribution of income to shareholders.